[Pediatric expert consensus on the application of aspirin in Kawasaki disease]

Area of Science:

• Pediatric Cardiology
• Rheumatology
• Immunology

Background:

• Kawasaki disease (KD) is a leading cause of acquired heart disease in young children.
• Acute systemic vasculitis in KD poses a risk for coronary artery lesions.
• Current first-line treatment involves intravenous immunoglobulin and oral aspirin, but optimal aspirin use remains debated.

Purpose of the Study:

• To establish consensus-based recommendations for aspirin use in acute Kawasaki disease.
• To address controversies regarding aspirin's role, dosage, and treatment duration.
• To provide guidance for preventing coronary artery lesions in KD patients.

Main Methods:

• Formulation of a consensus based on recent KD treatment research from China and internationally.
• Comprehensive discussions among Chinese pediatric experts.
• Review of current evidence on aspirin's efficacy and safety in KD management.

Main Results:

• The consensus provides specific recommendations on aspirin dosage for acute KD.
• Guidelines address the optimal usage and treatment course of aspirin.
• Evidence supports aspirin's role in preventing coronary artery lesions when used appropriately.

Conclusions:

• The consensus offers updated guidance for pediatricians managing Kawasaki disease.
• Standardized aspirin treatment protocols aim to improve patient outcomes.
• Further research may refine aspirin's role in KD management.